This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Videos and case studies: Clinical experience & patient cases​​​​​​​​​​​​​​

Listen to a selection of short videos where UK and international experts share their views on the role of ZAVICEFTA® (ceftazidime-avibactam), share their clinical experience through patient cases in cUTI, cIAI or HAP/VAP, and in general about the challenges and management of Gram-negative infections.

Dr Luke Moore

Dr Luke Moore, Infectious Diseases Consultant at Chelsea and Westminster presents a Pseudomonas and CRE patient case.

Dr Luke Moore

Dr Luke Moore, Infectious Diseases Consultant at Chelsea and Westminster presents his experience with ceftazidime-avibactam in MDR Pseudomonas before discussing a pneumonia-related patient case.

Dr Luke Moore & Miguel Sanchez Garcia

Dr Luke Moore and Miguel Sanchez Garcia discuss clinical effectiveness of ZAVICEFTA in treating severe Gram-negative infections.

Paschalis Vergidis

Listen to Paschalis Vergidis, Infectious Diseases Consultant at Manchester University NHS Foundation Trust, sharing his view on the challenges of MDR Gram-negative infections, and learn about his clinical experience managing a patient with renal transplant and the role of ceftazidime-avibactam in patients with cUTI.

Professor Jonathan Edgeworth

Listen to Professor Jonathan Edgeworth, Consultant Microbiologist from Guy & St. Thomas,  sharing his experience and difficulties with Gram-negative infections, the benefit of antibiotics to treat CRE and with efficacy vs MDR Pseudomonas. Learn about his experience with ceftazidime-avibactam in a patient with MDR Klebsiella (KPC and OXA 48).

Explore more

Access other case studies and videos

  • KOL Videos - Zavicefta
  • KOL Videos - Gram-negative
  • Webinars (Live & On-demand)
View Support & Services

Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; AMR, Antimicrobial Resistance

Prescribing information

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Meronem® (meropenem triydrate) IV 1g

Meronem® (meropenem triydrate) IV 500mg

Tazocin® (piperacillin sodium, tazobactam sodium) 2g/0.25g Powder for Solution for Infusion

Tazocin® (piperacillin sodium, tazobactam sodium) 4g/0.5g Powder for Solution for Infusion

Tygacil (tigecycline) 50mg powder for solution for infusion​​​​​​​

Zyvox® (linezolid) 2 mg/ml solution for infusion

Zyvox ® (linezolid) 100 mg/5 ml granules for oral suspension

Zyvox ® (linezolid) 600 mg film-coated tablets


Amikacin (amikacin sulfate) 500mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial pack £60.00
Click here for the Summary of Product Characteristics 


Gentamicin (gentamicin sulfate) 40 mg/ml Injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial £20.00 
Click here for the Summary of Product Characteristics


Ciprofloxacin (ciprofloxacin lactate) 2 mg/ml Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 bag £200.00 
Click here for the Summary of Product Characteristics

Tobramycin (tobramycin)
Tobramycin 240mg/6ml solution for injection
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 1 vial £19.20
Click here for the Summary of Product Characteristics

Tobramycin 80mg/2ml solution for injection 
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vial £20.80
​​​​​​​Click here for the Summary of Product Characteristics

PP-ZVA-GBR-0844. June 2021

Join us!

Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.

Register here

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

  • REPROVE Phase III trial (HAP/VAP)

  • RECLAIM Phase III trial (cIAI)

  • RECAPTURE Phase III trial (cUTI)​​​​​​​

  • REPRISE Phase III trial (cIAI and cUTI)

Learn more about the safety data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No